Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor

PURPOSE: To report the results of switching treatment to vascular endothelial growth factor (VEGF) Trap-Eye (aflibercept) in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) refractory to anti-VEGF (ranibizumab and bevacizumab). METHODS: This is a retros...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Korean J Ophthalmol
Autori principali: Moon, Da Ru Chi, Lee, Dong Kyu, Kim, Soon Hyun, You, Yong Sung, Kwon, Oh Woong
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Korean Ophthalmological Society 2015
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4520865/
https://ncbi.nlm.nih.gov/pubmed/26240506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3341/kjo.2015.29.4.226
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi